The purpose of this study is to reduce HIV transmission risk among people who inject drugs (PWID) through a multilevel intervention known as LIFT. LIFT intervenes to build intragroup PWID support at the community-level to reduce overall drug use and stigma. LIFT also increases efficacy in navigating HIV services in the presence of structural stigma. Additionally, LIFT intervenes on abstinence-based drug use stigma at the health facility-level to improve clinic policy and staff interactions with clients. This is an implementation study to adapt and pilot a stigma reduction intervention with persons who inject drugs (PWID) in Kyrgyzstan. The intervention includes peer-led group sessions focused on stigma reduction and providing support to increase HIV prevention efficacy. The aim will be to adapt, refine, and pilot the intervention among PWID and methadone maintenance treatment (MMT) clinic staff. Participants will be randomized to the intervention or control arms.
Kyrgyzstan is located within a region-Eastern Europe and Central Asia (EECA)-experiencing the world's most rapidly expanding HIV epidemic. Furthermore, this regional HIV epidemic is predominantly concentrated among persons who inject drugs (PWID). PWID face unique challenges engaging in the HIV care continuum. Intersecting stigmas related to HIV, drug use, and drug treatment (i.e., methadone maintenance therapy) uniquely amplify HIV risk in this population and impede engagement in effective HIV prevention services such as needle and syringe exchange programs, methadone maintenance therapy, and HIV antiretroviral therapy (among PWID with HIV) and Pre-exposure prophylaxis (PrEP; among PWID without HIV). Kyrgyzstan and the EECA are battling a growing HIV epidemic among PWID not seen in other regions. UNAIDS 2022 report states the EECA has one of the fastest growing HIV epidemics in the world, with a 48% increase in new infections since 2010. HIV prevalence among PWID in Kyrgyzstan is high (14.3% PWID vs. 0.2% general population), and HIV incidence is rapidly increasing among sex partners among whom the proportion of new infections increased from 63.0% in 2017 to 86.7% in 2022. Underreporting of stigmatized injection, and same-sex behaviors may partially explain this increase in HIV incidence attributed to sexual transmission. Female sex partners of PWID who reported no injection risk and HIV-negative partners had an HIV prevalence of 4.4% but an HCV prevalence of 13.0%, indicating a high probability of injection-related transmission risk. As a regional HIV service implementation leader, Kyrgyzstan's approach can inform future EECA HIV responses. Of the 16 UNAIDS-monitored EECA nations, SSP and MMT coverage is low in most, and MMT is illegal in three. MMT was the only form of opioid use disorder medication in seven EECA nations, including Kyrgyzstan although now buprenorphine is also offered as of August 2025. The historic roots of EECA addiction treatment stem from the punitive abstinence-focused legacy of the Soviet-era Narcology system, and MMT is more often seen as an effective HIV prevention tool than an effective drug use treatment given the emergence of MMT in the region via HIV service donor funding. Kyrgyzstan is one of the few EECA nations to provide free evidence-based HIV services nationally (HIV testing, SSP, MMT, antiretroviral therapy \[ART\], PrEP). Yet, the full HIV prevention power of these services remains untapped. The 2021 national surveillance data report 848 of \~25,000 PWID in Kyrgyzstan are using MMT, and 56% had consistent sterile syringe access. This is concerning as HIV testing is significantly tied to the recent use of these services. Few PWID (8.4%) are estimated to have received PrEP since 2020. Multilevel strategies to reduce stigma and improve uptake of evidence-based prevention services (e.g., MMT, PrEP) to lower HIV incidence among PWID in this region are needed. Similarly, the U.S. can learn how to increase HIV-related service use among PWID through interventions like LIFT, designed to reduce multilevel intersectional stigma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
80
LIFT intervention will include 5 peer-led participatory group sessions to reduce stigma and cultivate intragroup cohesion and support to increase HIV prevention efficacy. The intervention content will focus on 1) Naming the Problem (how intersectional stigma manifests and affects health outcomes), challenging myths that drive intersectional stigma and replacing myths with facts related to 2) Fears about drug use and internalized stigma (understanding drug dependence as a health condition), 3) Fears about MMT (understanding methadone treatment as a process, not a last resort), 4) Frears about HIV (understanding the health benefits of knowing ones HIV status and PrEP as a treatment to prevent HIV), and 5) Responding to intersectional stigma (challenging stigma and recognizing human rights and other protections for people who use drugs).
The LIFT intervention will be comprised of 2-day participatory trainings focused on reducing the drivers of stigma within healthcare settings and will cover the following topics: 1) Building awareness and knowledge of what drug use stigma looks like in maintenance vs. abstinence-focused MMT services, 2) Reducing HIV transmission and promoting healthier options with clients via PrEP and SSP health promotion service referrals, 3) Building stress management, empathy, and reducing social distancing in the clinic setting, and 4) Understanding institutional maintenance of stigma reduction practices and focusing on developing internal clinic policies and practices.
Public Foundation Den Sooluk Nuru
Bishkek, Kyrgyzstan
Overall drug use stigma
Changes in mean levels of overall drug use stigma among participants in the interventoin and control arm post-intervention will be measured as a mean composite score across multiple anticipated stigma sources (structural systems, family, healthcare workers, other people who inject/use drugs \[intragroup\]) and internalized drug use \[self\] stigma via the Substance Use Stigma Mechanisms Scale (SU-SMS)
Time frame: 6 months
Intragroup methadone maintenance treatment stigma
Changes in mean levels of intragroup methadone maintenance treatment \[MMT\] stigma among participants in the intervneton and control arm post-intervention will be measured as a mean composite score from the MMT Stigma Mechanisms Scale (MMT-SMS), anticipated stigma source (other people who inject/use drugs \[intragroup\])
Time frame: 6 months
Intragroup HIV stigma
Changes in mean levels of intragroup HIV stigma among participants in the interveniton and control arm post-intervention will be measured as a mean composite score from the HIV Stigma Mechanisms Scale (HIV-SMS), anticipated stigma source (other people who inject/use drugs \[intragroup\])
Time frame: 6 months
MOUD Use (including methadone and buprenorphine)
Frequency of participants in the intervention and control arm who self-report (Yes, No) taking methadone or buprenorphine medications for opioid use disorder (MOUD) post-intervention
Time frame: 6 months
PrEP Use
Frequency of participants in the intervention and control arm who self-report (Yes, No) taking pre-exposure prophylaxis (PrEP) post-intervention
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.